No Data
No Data
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
Express News | Chemomab Therapeutics Ltd : Maxim Group Initiates Coverage With Buy Rating; Target Price $4
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Express News | Chemomab Therapeutics Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q1 GAAP EPS Results
Express News | Chemomab Therapeutics Q1 2024 GAAP EPS $(0.28) Up From $(0.80) YoY
No Data